Intellipharmaceutics International Inc.
IPCIF · OTC
11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 | |
|---|---|---|---|---|
| Revenue | $66 | $66 | $1,402 | $1,402 |
| % Growth | 0% | -95.3% | 0% | – |
| Cost of Goods Sold | $0 | $256 | $431 | $33 |
| Gross Profit | $66 | -$191 | $971 | $1,368 |
| % Margin | 100% | -290.2% | 69.3% | 97.6% |
| R&D Expenses | $2,149 | $2,149 | $2,662 | $3,517 |
| G&A Expenses | $0 | $521 | $1,184 | $0 |
| SG&A Expenses | $561 | $561 | $1,250 | $2,147 |
| Sales & Mktg Exp. | $0 | $40 | $66 | $0 |
| Other Operating Expenses | $0 | $206 | $262 | $415 |
| Operating Expenses | $2,916 | $2,916 | $4,173 | $6,080 |
| Operating Income | -$2,851 | -$2,851 | -$4,173 | -$4,678 |
| % Margin | -4,336.8% | -4,336.8% | -297.8% | -333.8% |
| Other Income/Exp. Net | $255 | -$37 | -$1,086 | $1,320 |
| Pre-Tax Income | -$2,887 | -$2,887 | -$5,259 | -$3,358 |
| Tax Expense | $5 | $5 | -$114 | $33 |
| Net Income | -$2,892 | -$2,892 | -$5,145 | -$3,391 |
| % Margin | -4,400.6% | -4,400.6% | -367.1% | -241.9% |
| EPS | -0.087 | -0.098 | -0.22 | -0.16 |
| % Growth | 11.1% | 55.3% | -37.5% | – |
| EPS Diluted | -0.087 | -0.098 | -0.22 | -0.16 |
| Weighted Avg Shares Out | 33,093 | 29,430 | 23,562 | 21,580 |
| Weighted Avg Shares Out Dil | 33,093 | 29,430 | 23,562 | 21,580 |
| Supplemental Information | – | – | – | – |
| Interest Income | $292 | $549 | $970 | $14 |
| Interest Expense | $292 | $292 | $549 | $248 |
| Depreciation & Amortization | $213 | $256 | $431 | $507 |
| EBITDA | -$2,644 | -$2,644 | -$3,912 | -$1,763 |
| % Margin | -4,023.3% | -4,023.3% | -279.1% | -125.8% |